Clonidine is a
medication used to treat several medical conditions. It is a
direct-acting
α2
adrenergic agonist.
Uses
It has been prescribed historically as an
antihypertensive agent. It has found new uses, including
treatment of some types of
neuropathic pain,
opioid
detoxification,
sleep hyperhidrosis,
anaesthetic use, and
off-label, to counter the side effects of
stimulant medications such as
methylphenidate or
amphetamine. It is becoming a more accepted treatment for
insomnia, as well as for relief of
menopausal symptoms. Clonidine is increasingly used in
conjunction with stimulants to treat attention-deficit
hyperactivity disorder (ADHD),
for which it is administered in late afternoon or evening for
sleep, and because it sometimes helps moderate ADHD-associated
impulsive and oppositional behavior, and may reduce
tics.[1]
Clonidine can be used in the treatment of
Tourette syndrome.[2]
Clonidine is also a mild
sedative, and can be used as premedication before surgery or
procedures.
[3]
Mechanism
Clonidine treats high blood pressure by stimulating
α2 receptors in the brain, which decreases
cardiac output and
peripheral vascular resistance, lowering blood pressure. It
has specificity towards the
presynaptic α2 receptors in the
vasomotor center in the
brainstem. This binding decreases presynaptic
calcium levels, and inhibits the release of
norepinephrine (NE). The net effect is a decrease in
sympathetic tone.[4]
Indications & preparations
Clonidine tablets and transdermal patch
Clonidine is typically available as
tablets (Catapres, Dixarit), as a
transdermal patch (Catapres-TTS), or as an
injectable form to be given
epidurally, directly to the
central nervous system.
FDA approved
uses
This medication may also be used to ease withdrawal symptoms
associated with the long-term use of
narcotics,
alcohol and
nicotine (smoking). In addition, clonidine has also been
used for
migraine headaches, hot flashes associated with menopause,
and attention deficit hyperactivity disorder.[5][6]
Clonidine is regularly prescribed to
opiate addicts to help alleviate their withdrawal symptoms.
It is mainly used to combat the
sympathetic nervous system response to opiate withdrawal,
namely
tachycardia and
hypertension, in the initial days of withdrawals.[7]
It helps take away the sweating, hot/cold flashes, and general
restlessness. The sedation effect is also useful although its
side effects can include insomnia, thus exacerbating an already
common feature of opiate withdrawal.[8]
Off-Label Uses
Clonidine is used off-label to treat psychiatric disorders
including stress, sleep disturbances, and hyperarousal caused by
post-traumatic stress disorder, borderline personality disorder,
and other anxiety disorders.
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
Clonidine along with Methylphenidate has been studied for
treatment of ADHD.[18][19]
An extended-release version of clonidine named Clonicel is
also being studied for treatment of ADHD[20][21][22][23].
Adverse effects
This drug may cause lightheadedness, dry mouth, dizziness, or
constipation. Clonidine may also cause
hypotension[24]
Rebound hypertension on withdrawal
Clonidine suppresses sympathetic outflow resulting in lower
blood pressure, but sudden discontinuation can cause rebound
hypertension due to a rebound in sympathetic outflow.
Clonidine therapy should generally be gradually tapered off
when discontinuing therapy to avoid
rebound effects from occurring. Treatment of clonidine
withdrawal hypertension depends on the severity of the
condition. Reintroduction of clonidine for mild cases, alpha and
beta blockers for more urgent situations. Beta blockers never
should be used alone to treat clonidine withdrawal as alpha
vasoconstriction would still continue.[25][26]
Since ADHD drugs like amphetamine and methylphenidate tend to
stimulate the sympathetic nervous system,
missed doses of clonidine while under ADHD stimulant therapy
might entail increased risks of a more severe rebound
hypertension. This has not been evaluated.
Pharmacodynamics
Clonidine is a centrally-acting α-adrenergic
receptor agonist with more affinity for
α2 than
α1. It selectively stimulates receptors in the
brain that monitor
catecholamine levels in the blood. These receptors close a
negative feedback loop that begins with descending sympathetic
nerves from the brain that control the production of
catecholamines (epinephrine,
also known as adrenaline, and
norepinephrine) in the
adrenal medulla. By fooling the brain into believing that
catecholamine levels are higher than they really are, clonidine
causes the brain to reduce its signals to the adrenal medulla,
which in turn lowers catecholamine production and blood levels.
The result is a lowered heart rate and blood pressure, with side
effects of dry mouth and fatigue. If clonidine is suddenly
withdrawn the sympathetic nervous system will revert to
producing high levels of epinephrine and norepinephrine, higher
even than before treatment, causing
rebound hypertension. Rebound hypertension can be avoided by
slowly withdrawing treatment.
Clonidine suppression test
Clonidine's effect on reducing circulating epinephrine by a
central mechanism was used in the past as an investigatory test
for
pheochromocytoma,[27]
which is a catecholamine-synthesizing tumor, usually of the
adrenal medulla. In a clonidine suppression test plasma
catecholamines levels are measured before and 3 hours after a
0.3 µg/kg oral test dose has been given to a patient. A positive
test occurs if there is no decrease in plasma levels.
References
- ^
National Institute of Neurological Disorders and Stroke
(2002).
"Methylphenidate and Clonidine Help Children With ADHD
and Tics".
-
^ Schapiro NA.
"Dude, you don't have Tourette's": Tourette's syndrome,
beyond the tics. Pediatr Nurs. 2002
May-Jun;28(3):243-6, 249-53.
PMID 12087644
-
^ Fazi L. A
comparison of oral clonidine and oral midazolam as
preanesthetic medications in the pediatric tonsillectomy
patient. Anesth Analg. 2001 Jan;92(1):56-61.
PMID 11133600
-
^
Shen, Howard (2008).
Illustrated Pharmacology Memory Cards: PharMnemonics.
Minireview. pp. 12.
ISBN 1-59541-101-1.
-
^
"Clonidine Oral Uses". Web MD.
http://www.webmd.com/drugs/drug-11754-Clonidine.aspx?drugid=11754&drugname=Clonidine.
- ^
"Clonidine". Drugs.com.
http://www.drugs.com/clonidine.html.
- ^
. AJ Giannini. Drugs of Abuse--Second Edition. Los
Angeles, Practice Management Information
Corporation,1997.
- ^
AJ Giannini, I. Extein,MS Gold, ALC Pottash, S.
Castellani. Clonidine in mania. Drug Development
Research. 3:101-105,1983.
-
^
Ziegenhorn, A.; Roepke,
S.; Schommer, N.; Merkl, A.; Danker-Hopfe, H.; Perschel,
F.; Heuser, I.; Anghelescu, I. et al. (2009).
"Clonidine improves hyperarousal in borderline
personality disorder with or without comorbid
posttraumatic stress disorder: a randomized,
double-blind, placebo-controlled trial". Journal of
clinical psychopharmacology 29 (2): 170–173.
doi:10.1097/JCP.0b013e31819a4bae.
PMID 19512980. edit
-
^
Najjar, F; Weller, RA;
Weisbrot, J; Weller, EB (2008). "Post-traumatic stress
disorder and its treatment in children and adolescents".
Current psychiatry reports 10 (2): 104–8.
doi:10.1007/s11920-008-0019-0.
PMID 18474199. edit
-
^
Huffman, JC; Stern, TA
(2007). "Neuropsychiatric consequences of cardiovascular
medications". Dialogues in clinical neuroscience
9 (1): 29–45.
PMID 17506224. edit
-
^
Boehnlein, J.; Kinzie, J.
(2007). "Pharmacologic reduction of CNS noradrenergic
activity in PTSD: the case for clonidine and prazosin".
Journal of psychiatric practice 13 (2):
72–78.
doi:10.1097/01.pra.0000265763.79753.c1.
PMID 17414682. edit
-
^
Strawn, J.; Geracioti Jr,
T. (2008). "Noradrenergic dysfunction and the
psychopharmacology of posttraumatic stress disorder".
Depression and anxiety 25 (3): 260–271.
doi:10.1002/da.20292.
PMID 17354267. edit
-
^
Southwick, SM; Bremner,
JD; Rasmusson, A; Morgan Ca, 3rd; Arnsten, A; Charney,
DS (1999). "Role of norepinephrine in the
pathophysiology and treatment of posttraumatic stress
disorder". Biological psychiatry 46 (9):
1192–204.
doi:10.1016/S0006-3223(99)00219-X.
PMID 10560025. edit
-
^
Sutherland, SM; Davidson,
JR (1994). "Pharmacotherapy for post-traumatic stress
disorder". The Psychiatric clinics of North America
17 (2): 409–23.
PMID 7937367. edit
-
^
Van Der Kolk, BA (1987).
"The drug treatment of post-traumatic stress disorder".
Journal of affective disorders 13 (2):
203–13.
doi:10.1016/0165-0327(87)90024-3.
PMID 2960712. edit
- ^
"Understanding Comorbid Depression and Anxiety".
http://www.psychiatrictimes.com/anxiety/content/article/10168/53896?verify=0.
- ^
Daviss, W.; Patel, N.;
Robb, A.; McDermott, M.; Bukstein, O.; Pelham Jr, W.;
Palumbo, D.; Harris, P. et al. (2008). "Clonidine
for attention-deficit/hyperactivity disorder: II. ECG
changes and adverse events analysis". Journal of the
American Academy of Child and Adolescent Psychiatry
47 (2): 189–198.
doi:10.1097/chi.0b013e31815d9ae4.
PMID 18182964. edit
- ^
Palumbo, D.; Sallee, F.;
Pelham Jr, W.; Bukstein, O.; Daviss, W.; McDermott, M.
(2008). "Clonidine for attention-deficit/hyperactivity
disorder: I. Efficacy and tolerability outcomes".
Journal of the American Academy of Child and Adolescent
Psychiatry 47 (2): 180–188.
doi:10.1097/chi.0b013e31815d9af7.
PMID 18182963. edit
- ^
"Clinical Trials For Clonicel".
http://clinicaltrials.gov/ct2/show/NCT00641329.
- ^
"Clonicel Press Release".
http://www.drugs.com/nda/clonicel_091002.html.
- ^
"Addrenex's Clonicel Product Data".
http://www.addrenex.com/Addrenex-Clonicel-10-01-2009.pdf.
- ^
May, D.; Kratochvil, C.
(2010). "Attention-deficit hyperactivity disorder:
recent advances in paediatric pharmacotherapy". Drugs
70 (1): 15–40.
doi:10.2165/11530540-000000000-00000.
PMID 20030423. edit
- ^
Hossmann V; Maling TJ,
Hamilton CA, Reid JL, Dollery CT. (August 1980).
"Sedative and cardiovascular effects of clonidine and
nitrazepam". Clin Pharmacol Ther. 28 (2):
167–76.
PMID 7398184.
-
^
Keith Parker; Laurence
Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman,
Alfred (2006). Goodman & Gilman's the pharmacological
basis of therapeutics. New York: McGraw-Hill.
pp. 854–855.
ISBN 0-07-142280-3.
- ^
Vitiello B (April 2008).
"Understanding the risk of using medications for
attention deficit hyperactivity disorder with respect to
physical growth and cardiovascular function" (PDF).
Child Adolesc Psychiatr Clin N Am 17 (2):
459–74, xi.
doi:10.1016/j.chc.2007.11.010.
PMID 18295156.&
PMC 2408826.
http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2408826&blobtype=pdf.
-
^
Eisenhofer G, Goldstein
DS, Walther MM, et al. (June 2003).
"Biochemical diagnosis of pheochromocytoma: how to
distinguish true- from false-positive test results".
J. Clin. Endocrinol. Metab. 88 (6):
2656–66.
doi:10.1210/jc.2002-030005.
PMID 12788870.
http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=12788870.
|
[hide]
Adrenergics |
|
Receptor
Ligands |
|
|
Reuptake
Inhibitors |
|
|
Releasing
Agents |
Morpholines:
Phendimetrazine •
Phenmetrazine; Oxazolines:
4-Methylaminorex (4-MAR, 4-MAX) •
Aminorex •
Clominorex •
Cyclazodone •
Fenozolone •
Fluminorex •
Pemoline •
Thozalinone; Phenethylamines
(also Amphetamines, Cathinones,
Phentermines, etc):
2-Hydroxyphenethylamine (2-OH-PEA) •
4-Methylamphetamine (4-MA) •
4-Methylmethamphetamine (4-MMA) •
Alfetamine •
Amfecloral •
Amfepentorex •
Amfepramone •
Amphetamine ( Dextroamphetamine,
Levoamphetamine) •
Amphetaminil •
β-Methylphenethylamine (β-Me-PEA) •
Benzodioxolylbutanamine (BDB) •
Benzodioxolylhydroxybutanamine (BOH) •
Benzphetamine •
Buphedrone •
Butylone •
Cathine •
Cathinone •
Clobenzorex •
Clortermine •
D-Deprenyl •
Dimethoxyamphetamine (DMA) •
Dimethoxymethamphetamine (DMMA) •
Dimethylamphetamine •
Dimethylcathinone (Dimethylpropion,
Metamfepramone) •
Ephedrine (EPH) •
Ethcathinone (Ethylpropion) •
Ethylamphetamine •
Ethylbenzodioxolylbutanamine (EBDB) •
Ethylone •
Fenethylline •
Fenproporex •
Flephedrone •
Fludorex •
Furfenorex •
Hordenine •
Indanorex •
L-Deprenyl (Selegiline) •
Lisdexamfetamine •
Lophophine (Homomyristicylamine) •
Mefenorex •
Mephedrone •
Mephentermine •
Methamphetamine (Desoxyephedrine,
Methedrine;
Dextromethamphetamine,
Levomethamphetamine) •
Methcathinone (Methylpropion) •
Methedrone •
Methoxymethylenedioxyamphetamine (MMDA)
•
Methoxymethylenedioxymethamphetamine
(MMDMA) •
Methylbenzodioxolylbutanamine (MBDB) •
Methylenedioxyamphetamine (MDA;
Tenamfetamine) •
Methylenedioxyethylamphetamine (MDEA) •
Methylenedioxyhydroxyamphetamine (MDOH)
•
Methylenedioxymethamphetamine (MDMA) •
Methylenedioxymethylphenethylamine
(MDMPEA; Homarylamine) •
Methylenedioxyphenethylamine (MDPEA;
Homopiperonylamine) •
Methylone •
Ortetamine •
Parabromoamphetamine (PBA) •
Parachloroamphetamine (PCA) •
Parafluoroamphetamine (PFA) •
Parafluoromethamphetamine (PFMA) •
Parahydroxyamphetamine (PHA) •
Paraiodoamphetamine (PIA) •
Paramethoxyamphetamine (PMA) •
Paramethoxyethylamphetamine (PMEA) •
Paramethoxymethamphetamine (PMMA) •
Paredrine (Norpholedrine, Oxamphetamine)
•
Phenethylamine (PEA) •
Pholedrine •
Phenpentermine •
Phenpromethamine •
Phentermine •
Phenylpropanolamine (PPA) •
Prenylamine •
Propylamphetamine •
Pseudoephedrine (PSE) •
Tiflorex (Flutiorex) •
Tyramine (TRA) •
Xylopropamine •
Zylofuramine; Piperazines:
2,5-Dimethoxy-4-bromobenzylpiperazine
(2C-B-BZP) ���
Benzylpiperazine (BZP) •
Methoxyphenylpiperazine (MeOPP;
Paraperazine) ��
Methylbenzylpiperazine (MBZP) •
Methylenedioxybenzylpiperazine (MDBZP;
Piperonylpiperazine) •
Parafluorophenylpiperazine (pFPP;
Fluoperazine); Others:
2-Amino-1,2-dihydronaphthalene (2-ADN) •
2-Aminoindane (2-AI) •
2-Aminotetralin (2-AT) •
2-Benzylpiperidine (2-BP) •
4-Benzylpiperidine (4-BP) •
Clofenciclan •
Cyclopentamine ��
Cypenamine •
Cyprodenate •
Feprosidnine •
Gilutensin •
Heptaminol •
Hexacyclonate •
Indanylaminopropane (IAP) •
Isometheptene •
Methylhexanamine •
Naphthylaminopropane (NAP) •
Octodrine •
Phthalimidopropiophenone •
Propylhexedrine (PHX) •
Tuaminoheptane (Tuamine)
|
|
Enzyme
Inhibitors |
|
|
|
Others |
|
|